London: Scientists in the UK have infused blood cells grown in a laboratory into people in the first such clinical trial in the world. If proven safe and effective, manufactured blood cells could in time revolutionise treatments for people with blood disorders such as sickle cell and rare blood types, the researchers said.
It can be difficult to find enough well-matched donated blood for some people with these disorders, they said.
The team, including researchers from the University of Cambridge in the UK, said the blood cells were grown from stem cells from donors. red cells were then transfused into healthy volunteers.
This is the first time in the world that red blood cells that have been grown in a laboratory have been given to another person as part of a trial into blood transfusion, they said.
“We hope our lab grown red blood cells will last longer than those that come from blood donors,” said chief investigator Cedric Ghevaert, a professor at the University of Cambridge and NHS Blood and Transplant.
“If our trial, the first such in the world, is successful, it will mean that patients who currently require regular long-term blood transfusions will need fewer transfusions in future, helping transform their care,” Ghevaert said in a statement.
The trial is studying the lifespan of the lab grown cells compared with infusions of standard red blood cells from the same donor. The labgrown blood cells are all fresh, so the trial team expect them to perform better than a similar transfusion of standard donated red cells, which contains cells of varying ages, the researchers said. If manufactured cells last longer in the body, patients who regularly need blood may not need transfusions as often, reducing iron overload from frequent blood transfusions, which can lead to serious complications, they said.